Real-Life Indications of Interleukin-1 Blocking Agents in Hereditary Recurrent Fevers: Data From the JIRcohort and a Literature Review.
Adolescent
Adult
Aged
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antirheumatic Agents
/ therapeutic use
Child
Child, Preschool
Female
Hereditary Autoinflammatory Diseases
/ complications
Humans
Infant
Interleukin 1 Receptor Antagonist Protein
/ therapeutic use
Interleukin-1
/ antagonists & inhibitors
Male
Middle Aged
Retrospective Studies
Young Adult
anakinra
autoinflammatory diseases
canakinumab
hereditary recurrent fevers
indications
interleukin-1 blockers
treatment
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
07
2021
accepted:
19
10
2021
entrez:
3
12
2021
pubmed:
4
12
2021
medline:
18
12
2021
Statut:
epublish
Résumé
Interleukin (IL)-1 inhibitors represent the main treatment in patients with colchicine-resistant/intolerant familial Mediterranean fever (crFMF), mevalonate kinase deficiency (MKD), and tumor necrosis factor receptor-associated periodic syndrome (TRAPS). However, the reasons for the use of IL-1 inhibitors in these diseases are still not completely clarified. Identify real-life situations that led to initiating anakinra or canakinumab treatment in hereditary recurrent fevers (HRFs), combining data from an international registry and an up-to-date literature review. Data were extracted from the JIRcohort, in which clinical information (demographic data, treatment, disease activity, and quality of life) on patients with FMF, MKD, and TRAPS was retrospectively collected. A literature search was conducted using Medline, EMBASE, and Cochrane databases. Complete data of 93 patients with HRF (53.8% FMF, 31.2% MKD, and 15.1% TRAPS) were analyzed. Data from both the registry and the literature review confirmed that the main reasons for use of IL-1 blockers were the following: failure of previous treatment (n = 57, 61.3% and n = 964, 75.3%, respectively), persistence of disease activity with frequent attacks (n = 44, 47.3% and n = 1,023, 79.9%) and/or uncontrolled inflammatory syndrome (n = 46, 49.5% and n = 398, 31.1%), severe disease complication or associated comorbidities (n = 38, 40.9% and n = 390, 30.4%), and worsening of patients' quality of life (n = 36, 38.7% and n = 100, 7,8%). No reasons were specified for 12 (16.4%) JIRcohort patients and 154 (12%) patients in the literature. In the absence of standardized indications for IL-1 inhibitors in crFMF, MKD, and TRAPS, these results could serve as a basis for developing a treat-to-target strategy that would help clinicians codify the therapeutic escalation with IL-1 inhibitors.
Sections du résumé
Background
Interleukin (IL)-1 inhibitors represent the main treatment in patients with colchicine-resistant/intolerant familial Mediterranean fever (crFMF), mevalonate kinase deficiency (MKD), and tumor necrosis factor receptor-associated periodic syndrome (TRAPS). However, the reasons for the use of IL-1 inhibitors in these diseases are still not completely clarified.
Objective
Identify real-life situations that led to initiating anakinra or canakinumab treatment in hereditary recurrent fevers (HRFs), combining data from an international registry and an up-to-date literature review.
Patients and Methods
Data were extracted from the JIRcohort, in which clinical information (demographic data, treatment, disease activity, and quality of life) on patients with FMF, MKD, and TRAPS was retrospectively collected. A literature search was conducted using Medline, EMBASE, and Cochrane databases.
Results
Complete data of 93 patients with HRF (53.8% FMF, 31.2% MKD, and 15.1% TRAPS) were analyzed. Data from both the registry and the literature review confirmed that the main reasons for use of IL-1 blockers were the following: failure of previous treatment (n = 57, 61.3% and n = 964, 75.3%, respectively), persistence of disease activity with frequent attacks (n = 44, 47.3% and n = 1,023, 79.9%) and/or uncontrolled inflammatory syndrome (n = 46, 49.5% and n = 398, 31.1%), severe disease complication or associated comorbidities (n = 38, 40.9% and n = 390, 30.4%), and worsening of patients' quality of life (n = 36, 38.7% and n = 100, 7,8%). No reasons were specified for 12 (16.4%) JIRcohort patients and 154 (12%) patients in the literature.
Conclusion
In the absence of standardized indications for IL-1 inhibitors in crFMF, MKD, and TRAPS, these results could serve as a basis for developing a treat-to-target strategy that would help clinicians codify the therapeutic escalation with IL-1 inhibitors.
Identifiants
pubmed: 34858402
doi: 10.3389/fimmu.2021.744780
pmc: PMC8632237
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antirheumatic Agents
0
Interleukin 1 Receptor Antagonist Protein
0
Interleukin-1
0
canakinumab
37CQ2C7X93
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
744780Informations de copyright
Copyright © 2021 Vinit, Georgin-Lavialle, Theodoropoulou, Barbier, Belot, Mejbri, Pillet, Pachlopnik, Poignant, Rebelle, Woerner, Koné-Paut and Hentgen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Rheumatology (Oxford). 2021 Jun 18;60(6):2878-2883
pubmed: 34144604
Ann Rheum Dis. 2007 Nov;66(11):1545-6
pubmed: 17934085
Mod Rheumatol. 2015 Jul;25(4):621-4
pubmed: 25528863
Drug Des Devel Ther. 2015 Apr 17;9:1983-7
pubmed: 25945034
Ann Rheum Dis. 2011 Sep;70(9):1692-3
pubmed: 21378401
Clin Rheumatol. 2018 Aug;37(8):2233-2240
pubmed: 29770930
Clin Rheumatol. 2014 Nov;33(11):1681-4
pubmed: 24531849
Pediatrics. 2012 Feb;129(2):e535-9
pubmed: 22271696
J Med Genet. 2018 Aug;55(8):530-537
pubmed: 29599418
Semin Arthritis Rheum. 2005 Aug;35(1):57-64
pubmed: 16084225
Neth J Med. 2008 Dec;66(11):489-91
pubmed: 19075317
Am J Med Genet. 1998 Jan 13;75(2):216-9
pubmed: 9450890
Rheumatol Int. 2015 Nov;35(11):1943-7
pubmed: 26048626
Am J Med. 2004 Aug 1;117(3):208-10
pubmed: 15300976
Arthritis Rheum. 2008 May;58(5):1516-20
pubmed: 18438813
North Clin Istanb. 2019 Nov 21;7(1):78-80
pubmed: 32232210
Ann Rheum Dis. 2014 Dec;73(12):2168-73
pubmed: 24026675
Joint Bone Spine. 2017 Mar;84(2):159-162
pubmed: 27238193
Ann Rheum Dis. 2013 Jan;72(1):155
pubmed: 22887853
Ann Rheum Dis. 2009 Feb;68(2):246-8
pubmed: 18801759
Rheumatol Int. 2015 Oct;35(10):1733-7
pubmed: 26001859
Rheumatology (Oxford). 2012 Oct;51(10):1855-9
pubmed: 22740624
Int J Rheum Dis. 2018 Oct;21(10):1849-1856
pubmed: 28560764
Medicine (Baltimore). 2008 Nov;87(6):301-310
pubmed: 19011501
Arthritis Care Res (Hoboken). 2017 Apr;69(4):578-586
pubmed: 27723279
Rheumatology (Oxford). 2021 Mar 2;60(3):1563-1564
pubmed: 33347575
Semin Arthritis Rheum. 2011 Oct;41(2):265-71
pubmed: 21277619
Ann Intern Med. 2007 Jun 5;146(11):825-6
pubmed: 17548423
Rheumatol Int. 2018 May;38(5):879-885
pubmed: 29450637
Isr Med Assoc J. 2012 Apr;14(4):229-31
pubmed: 22675839
N Engl J Med. 2018 May 17;378(20):1908-1919
pubmed: 29768139
Rheumatol Int. 2018 Jan;38(1):75-81
pubmed: 29138905
Dermatol Online J. 2013 Nov 15;19(11):20405
pubmed: 24314780
Ann Rheum Dis. 2014 May;73(5):897-901
pubmed: 24570027
Mod Rheumatol. 2016;26(3):458-9
pubmed: 24533541
Rheumatology (Oxford). 2009 Apr;48(4):395-8
pubmed: 19193696
J Clin Rheumatol. 2020 Jan;26(1):7-13
pubmed: 30048391
Pediatrics. 2014 Feb;133(2):e461-5
pubmed: 24470648
BMC Pediatr. 2019 Jul 20;19(1):245
pubmed: 31325964
Arthritis Res Ther. 2015 Sep 04;17:243
pubmed: 26337145
North Clin Istanb. 2021 Apr 26;8(3):255-260
pubmed: 34222806
J Allergy Clin Immunol Pract. 2021 Aug;9(8):3218-3220.e1
pubmed: 33857659
J Nephrol. 2018 Jun;31(3):453-455
pubmed: 29446001
Ann Allergy Asthma Immunol. 2018 Feb;120(2):214-215
pubmed: 29290516
Rheumatology (Oxford). 2021 Mar 14;:
pubmed: 33715002
Front Pharmacol. 2016 Oct 24;7:380
pubmed: 27822185
Arthritis Rheum. 2012 Mar;64(3):908-13
pubmed: 22006113
Turk J Med Sci. 2021 May 7;51(5):2357-2363
pubmed: 33957721
Clin Exp Rheumatol. 2021 Sep-Oct;39 Suppl 132(5):30-36
pubmed: 34251317
Eur J Pediatr. 2008 Jun;167(6):695-6
pubmed: 17588171
Pediatrics. 2011 Jul;128(1):e152-9
pubmed: 21708801
Rheumatology (Oxford). 2007 Dec;46(12):1860-2
pubmed: 17965046
Front Med (Lausanne). 2021 Jul 08;8:668173
pubmed: 34307404
Front Immunol. 2020 Jun 03;11:865
pubmed: 32655539
Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9982-7
pubmed: 16785446
Annu Rev Med. 2014;65:223-44
pubmed: 24422572
Mod Rheumatol. 2019 Mar;29(2):363-366
pubmed: 29578360
Eur J Pediatr. 2015 Jun;174(6):707-14
pubmed: 25721923
J Rheumatol. 2008 Feb;35(2):357-8
pubmed: 18260167
Transplantation. 2010 Jul 15;90(1):102-3
pubmed: 20606570
Ann Rheum Dis. 2016 Jun;75(6):1051-6
pubmed: 26823530
Mol Cell Pediatr. 2016 Dec;3(1):33
pubmed: 27590627
Int J Rheum Dis. 2017 Apr;20(4):510-514
pubmed: 27990755
Front Immunol. 2021 Feb 01;11:619257
pubmed: 33603750
ACG Case Rep J. 2019 Jul 29;6(7):e00143
pubmed: 31620540
Rheumatology (Oxford). 2017 Jan;56(1):167-169
pubmed: 27576367
Transplant Proc. 2016 Jan-Feb;48(1):265-6
pubmed: 26915881
J Inflamm Res. 2020 Mar 09;13:141-149
pubmed: 32210604
Arthritis Rheumatol. 2014 Nov;66(11):3241-3
pubmed: 25049046
Rheumatol Int. 2013 Jul;33(7):1713-9
pubmed: 23274441
Nephrol Dial Transplant. 2009 Feb;24(2):676-8
pubmed: 19033248
Ann Rheum Dis. 2017 Jan;76(1):173-178
pubmed: 27269295
Scand J Rheumatol. 2017 Sep;46(5):407-409
pubmed: 28097903
Eur J Clin Invest. 2007 Nov;37(11):912-4
pubmed: 17973784
Eur Rev Med Pharmacol Sci. 2013 Apr;17(7):958-63
pubmed: 23640444
Eur J Rheumatol. 2018 Dec;5(4):230-234
pubmed: 30501849
Mod Rheumatol. 2016 Sep;26(5):637-41
pubmed: 26939747
Arthritis Rheumatol. 2016 Nov;68(11):2795-2805
pubmed: 27213830
N Engl J Med. 2003 Jun 19;348(25):2583-4
pubmed: 12815153
Bratisl Lek Listy. 2018;119(4):198-200
pubmed: 29663815
Ann Rheum Dis. 2019 Aug;78(8):1025-1032
pubmed: 31018962
Clin Transplant. 2021 Jun;35(6):e14309
pubmed: 33813772
Pediatrics. 2013 Sep;132(3):e779-83
pubmed: 23979089
Int J Rheum Dis. 2015 May;18(4):473-5
pubmed: 25522898
Ann Intern Med. 2012 Jun 19;156(12):907-8
pubmed: 22711098
Ital J Pediatr. 2019 Aug 23;45(1):111
pubmed: 31443670
Clin Rheumatol. 2016 Feb;35(2):441-6
pubmed: 25213327
Case Rep Rheumatol. 2013;2013:795027
pubmed: 23691418
Pediatrics. 2007 Feb;119(2):e523-7
pubmed: 17261617
Clin Exp Rheumatol. 2013 May-Jun;31(3 Suppl 77):99-102
pubmed: 24064022
Clin Transplant. 2018 Aug;32(8):e13345
pubmed: 29981275
Gene. 2014 Jun 1;542(2):217-20
pubmed: 24656624
Rheumatology (Oxford). 2007 Jul;46(7):1211-2
pubmed: 16935919
Neth J Med. 2016 Jan;74(1):43-6
pubmed: 26819362
Acta Paediatr. 2011 Jan;100(1):21-5
pubmed: 20712835
Arthritis Rheum. 2007 Feb;56(2):658-61
pubmed: 17265501
Ann Rheum Dis. 2013 May;72(5):678-85
pubmed: 22753383
Clin Kidney J. 2014 Apr;7(2):219-20
pubmed: 25852877
J Rheumatol. 2018 Mar;45(3):425-429
pubmed: 29335349
Nefrologia. 2012;32(6):865-6
pubmed: 23169386
Arthritis Rheumatol. 2017 Apr;69(4):854-862
pubmed: 27860460
Eur J Neurol. 2011 Sep;18(9):1146-50
pubmed: 21299735
Rheumatol Int. 2011 May;31(5):623-8
pubmed: 20049448
PLoS One. 2009 Sep 28;4(9):e7154
pubmed: 19784369
Clin Rheumatol. 2015 Apr;34(4):807-9
pubmed: 24609716
Arthritis Care Res (Hoboken). 2018 Jul;70(7):1090-1094
pubmed: 28992387
Arthritis Rheum. 2006 Jun;54(6):2010-4
pubmed: 16732551
J Rheumatol. 2017 Jan;44(1):102-109
pubmed: 28042127
J Allergy Clin Immunol Pract. 2015 Sep-Oct;3(5):817-8
pubmed: 26116953
Arthritis Res Ther. 2013 Jan 28;15(1):R21
pubmed: 23356447
Cell. 1999 Apr 2;97(1):133-44
pubmed: 10199409
Eur J Intern Med. 2017 Apr;39:75-78
pubmed: 27776949
Arthritis Rheum. 2013 Apr;65(4):1116-21
pubmed: 23280696
Clin Exp Rheumatol. 1997 Jul-Aug;15(4):355-60
pubmed: 9272294
Neth J Med. 2005 Jul-Aug;63(7):260-4
pubmed: 16093577
Rheumatology (Oxford). 2012 Jun;51(6):1041
pubmed: 22403182
Orphanet J Rare Dis. 2015 Feb 15;10:19
pubmed: 25758134
Arthritis Rheumatol. 2017 Aug;69(8):1679-1688
pubmed: 28482144
Semin Arthritis Rheum. 2013 Dec;43(3):387-91
pubmed: 23742958
J Clin Hypertens (Greenwich). 2008 May;10(5):348-54
pubmed: 18453793
J Invest Dermatol. 2017 Sep;137(9):2019-2021
pubmed: 28499757
Mediators Inflamm. 2020 Aug 7;2020:8562485
pubmed: 32831641
Nephrol Dial Transplant. 2012 May;27(5):1898-901
pubmed: 21931121
J Rheumatol. 1997 Feb;24(2):323-7
pubmed: 9034991
Rheumatol Int. 2012 Jun;32(6):1801-4
pubmed: 20352226
Paediatr Drugs. 2017 Aug;19(4):303-311
pubmed: 28497352
Mod Rheumatol. 2020 Jan;30(1):166-171
pubmed: 30556769
Rheumatology (Oxford). 2015 Sep;54(9):1749-51
pubmed: 26078218
Clin Exp Rheumatol. 2009 Mar-Apr;27(2 Suppl 53):S96-101
pubmed: 19796543
Transpl Int. 2018 Oct;31(10):1181-1184
pubmed: 29957882
Pediatr Rheumatol Online J. 2016 Mar 25;14(1):19
pubmed: 27012807
Clin Rev Allergy Immunol. 2013 Aug;45(1):117-30
pubmed: 23322405
Ann Rheum Dis. 2015 Sep;74(9):1636-44
pubmed: 26109736
Clin Rheumatol. 2010 Feb;29(2):209-10
pubmed: 19774408
Joint Bone Spine. 2013 Dec;80(6):645-9
pubmed: 23928237
Front Pediatr. 2017 Jun 07;5:128
pubmed: 28638818
Nefrologia. 2016;36(1):63-6
pubmed: 26409501
Front Immunol. 2020 May 13;11:889
pubmed: 32477360
Ann Rheum Dis. 2011 Aug;70(8):1511-2
pubmed: 21173015
Rheumatology (Oxford). 2021 Aug 2;60(8):3799-3808
pubmed: 33331943
Arthritis Care Res (Hoboken). 2015 Aug;67(8):1173-9
pubmed: 25469482
Arthritis Rheum. 2011 Apr;63(4):1141-50
pubmed: 21225694
Ann Rheum Dis. 2011 Dec;70(12):2155-8
pubmed: 21859689
Inflammation. 2015 Feb;38(1):27-31
pubmed: 25139580
Mod Rheumatol. 2017 Mar;27(2):350-355
pubmed: 27328763
Eur J Rheumatol. 2019 Apr 1;6(2):85-88
pubmed: 31365342
Isr Med Assoc J. 2014 May;16(5):281-4
pubmed: 24979831
Rheumatol Int. 2016 Jul;36(7):1011-3
pubmed: 26965418
Ann Rheum Dis. 2016 Apr;75(4):644-51
pubmed: 26802180
Clin Rheumatol. 2017 Jul;36(7):1687-1690
pubmed: 28536823
Reumatol Clin. 2017 Mar - Apr;13(2):120-121
pubmed: 27377451
Rheumatol Int. 2012 Jan;32(1):249-51
pubmed: 20020131
Mod Rheumatol. 2019 Jan;29(1):181-187
pubmed: 29451047
J Rheumatol. 2011 Mar;38(3):516-8
pubmed: 21159830
J Inherit Metab Dis. 2006 Dec;29(6):763
pubmed: 17103011
Joint Bone Spine. 2008 Jul;75(4):504-5
pubmed: 18541452
Orphanet J Rare Dis. 2017 Mar 16;12(1):54
pubmed: 28302131
Semin Arthritis Rheum. 2017 Aug;47(1):115-120
pubmed: 28413100
Rheumatol Int. 2012 Oct;32(10):3277-9
pubmed: 20386914